Vanda Gains EMA Orphan Status for Imsidolimab in GPP
WASHINGTON, July 16, 2026 Vanda Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) at the European...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WASHINGTON, July 16, 2026 Vanda Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) at the European...
INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
